263 related articles for article (PubMed ID: 35511180)
1. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
[TBL] [Abstract][Full Text] [Related]
3. Difelikefalin for Hemodialysis Patients with Pruritus in Japan.
Narita I; Tsubakihara Y; Takahashi N; Ebata T; Uchiyama T; Marumo M; Okamura S; Gejyo F;
NEJM Evid; 2023 Nov; 2(11):EVIDoa2300094. PubMed ID: 38320524
[TBL] [Abstract][Full Text] [Related]
4. Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study.
Weiner DE; Vervloet MG; Walpen S; Schaufler T; Munera C; Menzaghi F; Wen W; Bhaduri S; Germain MJ;
Kidney Med; 2022 Oct; 4(10):100542. PubMed ID: 36185706
[TBL] [Abstract][Full Text] [Related]
5. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.
Fishbane S; Mathur V; Germain MJ; Shirazian S; Bhaduri S; Munera C; Spencer RH; Menzaghi F;
Kidney Int Rep; 2020 May; 5(5):600-610. PubMed ID: 32405581
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
Topf J; Wooldridge T; McCafferty K; Schömig M; Csiky B; Zwiech R; Wen W; Bhaduri S; Munera C; Lin R; Jebara A; Cirulli J; Menzaghi F
Kidney Med; 2022 Aug; 4(8):100512. PubMed ID: 36016762
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
Kim BS; Bissonnette R; Nograles K; Munera C; Shah N; Jebara A; Cirulli J; Goncalves J; Lebwohl M;
N Engl J Med; 2023 Feb; 388(6):511-517. PubMed ID: 36780675
[TBL] [Abstract][Full Text] [Related]
9. Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial.
Fotheringham J; Guest J; Latus J; Lerma E; Morin I; Schaufler T; Soro M; Ständer S; Zeig S
Patient; 2024 Mar; 17(2):203-213. PubMed ID: 38196014
[TBL] [Abstract][Full Text] [Related]
10. Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2.
Fishbane S; Clegg DJ; Lerma EV; Rastogi A; Budden J; Morin I; Wen W; Menzaghi F; Topf J
Am J Nephrol; 2024; 55(3):329-333. PubMed ID: 38253036
[TBL] [Abstract][Full Text] [Related]
11. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.
Fugal J; Serpa SM
Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review.
Xue G; Yuan H; Fan D; Yang Y; Ma C; Liu J; Liao R
Clin Nephrol; 2024 Apr; 101(4):155-163. PubMed ID: 38294219
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the physical dependence potential of difelikefalin: Randomized placebo-controlled study in patients receiving hemodialysis.
Spencer RH; Munera C; Shram MJ; Menzaghi F
Clin Transl Sci; 2023 Sep; 16(9):1559-1568. PubMed ID: 37128642
[TBL] [Abstract][Full Text] [Related]
14. Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review.
Wala K; Szepietowski JC
Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015082
[TBL] [Abstract][Full Text] [Related]
15. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.
Rastogi A; Fishbane S; Lerma E
Expert Rev Clin Pharmacol; 2023 May; 16(5):387-400. PubMed ID: 37010031
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.
Fishbane S; Wen W; Munera C; Lin R; Bagal S; McCafferty K; Menzaghi F; Goncalves J
Kidney Med; 2022 Aug; 4(8):100513. PubMed ID: 36039153
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
18. [Difelikefalin and treatment of severe pruritus associated with chronic kidney disease - Real-life retrospective study in a dialysis center].
Brasme R; Cartery C; Goubet M; Hennino MF; Maisonneuve N
Nephrol Ther; 2024 Jun; 20(3):1-9. PubMed ID: 38874419
[TBL] [Abstract][Full Text] [Related]
19. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
[TBL] [Abstract][Full Text] [Related]
20. Intravenous difelikefalin for the treatment of hemodialysis pruritus.
Mahmoud RH; Mahmoud O; Yosipovitch G
Expert Rev Clin Immunol; 2024; 20(1):31-37. PubMed ID: 37847514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
